Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME.

J Drugs Dermatol. 2012 Nov;11(11):e61-5.

PMID:
23135095
2.

Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.

Li JR, Yang CR, Cheng CL, Ho HC, Chiu KY, Su CK, Chen WM, Wang SS, Chen CS, Yang CK, Ou YC.

Support Care Cancer. 2013 Mar;21(3):907-11. doi: 10.1007/s00520-012-1693-3. Epub 2012 Dec 21.

PMID:
23262811
3.

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.

McLellan B, Kerr H.

Dermatol Ther. 2011 Jul-Aug;24(4):396-400. doi: 10.1111/j.1529-8019.2011.01435.x. Review.

PMID:
21910797
4.

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Lacouture ME, Reilly LM, Gerami P, Guitart J.

Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.

PMID:
18550575
5.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group..

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

PMID:
22700990
6.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
7.

Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S, Kamba T, Yamasaki T, Ogawa O, Seno H, Chiba T, Matsubara K.

Clin Pharmacokinet. 2014 Feb;53(2):185-96. doi: 10.1007/s40262-013-0108-z.

PMID:
24135988
8.

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.

Urol Oncol. 2013 Nov;31(8):1800-5. doi: 10.1016/j.urolonc.2012.04.019. Epub 2012 May 31.

PMID:
22658883
9.

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.

Sil A, Das NK.

Indian J Pharmacol. 2014 May-Jun;46(3):334-6. doi: 10.4103/0253-7613.132189.

10.

Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.

Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Guo X, Ye SL.

J Clin Oncol. 2015 Mar 10;33(8):894-900. doi: 10.1200/JCO.2013.52.9651. Epub 2015 Feb 9.

PMID:
25667293
11.

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.

Massey PR, Okman JS, Wilkerson J, Cowen EW.

Support Care Cancer. 2015 Jun;23(6):1827-35. doi: 10.1007/s00520-014-2520-9. Epub 2014 Dec 5. Review.

12.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP.

Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. Review.

13.

A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.

Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, Naito S.

Ann Oncol. 2014 Feb;25(2):472-6. doi: 10.1093/annonc/mdt541. Epub 2013 Dec 18.

PMID:
24351402
14.

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.

15.

Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.

Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A.

Cancer Chemother Pharmacol. 2014 Feb;73(2):381-8. doi: 10.1007/s00280-013-2360-1. Epub 2013 Dec 4.

PMID:
24306119
16.

The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.

Anderson RT, Keating KN, Doll HA, Camacho F.

Oncologist. 2015 Jul;20(7):831-8. doi: 10.1634/theoncologist.2014-0219. Epub 2015 Jun 17.

17.

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009. Epub 2012 Nov 6.

PMID:
23140824
18.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
19.

Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.

Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW.

Dermatol Surg. 2013 Jul;39(7):981-7. doi: 10.1111/dsu.12184. Epub 2013 Mar 6. Review.

PMID:
23464361
20.

[Hand-foot syndrome after administration of tyrosinkinase inhibitors].

Bednaríková D, Kocák I.

Klin Onkol. 2010;23(5):300-5. Review. Czech.

PMID:
21061680

Supplemental Content

Support Center